Latest Hotspot

ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab

24 April 2024
3 min read

ASLAN Pharmaceuticals, a biopharmaceutical firm at the clinical stage with a focus on immunology, today disclosed encouraging preliminary outcomes from the TREK-DX Phase 2 trial, which examines eblasakimab in adults with moderate-to-severe atopic dermatitis who had prior treatments with dupilumab. The company specializes in creating novel therapies aimed at enhancing patient health.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The primary outcome of the study, the change in Eczema Area Severity Index (EASI) score from the start to week 16, demonstrated significant differences when compared with the control group receiving placebo, despite the early analysis not being statistically significant owing to the size of the sample group. A 73.3% majority of patients treated with eblasakimab saw their EASI scores decrease by at least 75% from initial levels, in contrast to only 14.3% of those receiving a placebo.

Dr. Carl Firth, CEO of ASLAN Pharmaceuticals, expressed great satisfaction with the outcomes. "The results from eblasakimab in higher dosing regimens surpass previous studies. The majority of eblasakimab participants reached both EASI-90 and vIGA scores of 0 or 1 within 16 weeks, a milestone not seen in other biologic studies for AD. Eblastakimab was particularly effective in patients unresponsive to prior dupilumab treatment, with two-thirds reaching EASI-90 and vIGA scores of 0 or 1."

Dr. Firth also added, "The anticipated year-end announcement of the comprehensive results from the TREK-DX study, a pioneering placebo-controlled trial involving AD patients previously treated with dupilumab, will be a significant milestone. We also aim to refine the dosing approach for eblasakimab in the upcoming Phase 3 trials."

Eblasakimab, a pioneering monoclonal antibody directed at the IL-13 receptor subunit of the Type 2 receptor, holds promise as an innovative treatment for various allergic inflammatory diseases by disrupting a crucial inflammatory pathway. Its distinct mode of action is designed to enhance the efficacy over existing biologics that manage these conditions.

By targeting the Type 2 receptor, eblasakimab interferes with the inflammatory signals mediated by interleukin 4 and interleukin 13, pivotal in the pathogenesis of AD and Type 2-driven Chronic Obstructive Pulmonary Disease (COPD). In July 2023, positive findings from the TREK-AD Phase 2b study examining eblasakimab in patients with moderate-to-severe, biologic-naïve AD were announced by ASLAN. The current TREK-DX Phase 2 trial is evaluating eblasakimab in moderate-to-severe AD patients experienced with dupilumab. 

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of April 23, 2024, there are 2 investigational drugs for the IL-13Rα1 target, including 4 indications, 5 R&D institutions involved, with related clinical trials reaching 4, and as many as 1562 patents.

Eblasakimab targets IL-13Rα1 and has shown potential in treating immune system diseases, congenital disorders, skin and musculoskeletal diseases, and respiratory diseases. Currently in Phase 2, Eblasakimab is still undergoing clinical trials to determine its safety and efficacy. If successful, it could provide new treatment options for patients in need.

图形用户界面, 文本, 应用程序

描述已自动生成

Compilation of 13 FDA-Approved ADC (Antibody-Drug Conjugate) Medications
Graphic Pharma
19 min read
Compilation of 13 FDA-Approved ADC (Antibody-Drug Conjugate) Medications
24 April 2024
At present, 13 types of ADCs have been approved by the United States Food and Drug Administration (FDA), with over 200 additional ADCs at various stages of clinical trials.
Read →
AGA China Phase II Study GT20029 Successfully Meets Its Primary Goal
Latest Hotspot
3 min read
AGA China Phase II Study GT20029 Successfully Meets Its Primary Goal
24 April 2024
Kintor Pharmaceutical Limited announced that its innovative proteolysis targeting chimera compound, GT20029, targeting the androgen receptor (AR), has achieved the primary endpoint in a phase II trial in China.
Read →
What is ED50?
"What" Series
2 min read
What is ED50?
24 April 2024
ED50 (Effective Dose 50) refers to the dose of a drug or substance that produces a desired effect in 50% of a population or sample under a given set of experimental conditions or in a group of test subjects.
Read →
EU Commission Approves BIMZELX® for Hidradenitis Suppurativa, First Biologic Targeting IL-17A and IL-17F
Latest Hotspot
3 min read
EU Commission Approves BIMZELX® for Hidradenitis Suppurativa, First Biologic Targeting IL-17A and IL-17F
24 April 2024
The European Commission has granted UCB approval for BIMZELX®(bimekizumab), marking it as the initial biologic targeting both IL-17A and IL-17F for treating moderate to severe hidradenitis suppurativa.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.